Method for alleviating keratoconjunctivitis sicca

A nasal mucosa, compound technology, applied in the direction of anti-inflammatory agents, pharmaceutical formulations, organic active ingredients, etc., can solve the problems of blurred vision, local irritation, burning sensation and stinging pain

Inactive Publication Date: 2009-12-30
WINSTON LAB
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Artificial tear eye drops and cyclosporine eye drops often cause local

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Thirty (30) normal volunteers were divided into 3 separate individual groups of 10 individuals in a multiple-dose 14-day tolerability study evaluating 0.0075% by weight civamide nasal spray administered twice daily Local action of 0.01% by weight civamide administered twice daily and 0.015% by weight civamide administered once daily. For the two groups receiving civamide twice daily, 10 out of 10 individuals in each group (100%) stated that they experienced an increase in lacrimation (tear production), whereas for the group receiving 0.015% civamide by weight once daily group, 9 out of 10 subjects (90%) experienced increased tearing.

Embodiment 2

[0019] Fifty-five (55) patients with vasomotor rhinitis (non-allergic rhinitis) participated in a double-blind placebo-controlled two-week symptom relief assessment trial in which patients received civamide nasal spray 0.01% by weight or placebo nasal Spray (carrier for active product). Among patients using 0.01% by weight civamide spray, 31% of patients reported increased tearing, while among patients using placebo, 0% of patients noted such side effects.

Embodiment 3

[0021] Thirty-four (34) migraine patients were administered a 0.025% by weight capsaicin cream to the nasal mucosa to relieve their headaches. Four hours after applying the 0.025% by weight capsaicin cream, 73% of the patients noted some relief in their headaches. Increased lacrimation was reported as a side effect by 44% of patients.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An improved method of increasing tear production is by intranasally administering a therapeutically effective amount of a capsaicinoid compound to patients with deficient tear production. Optional incorporation into the intranasal formulation of a topical corticosteroid or topical anesthetic compound is used to reduce transient nasal stinging and burning which may sometimes accompany intranasal administration of capsaicinoids.

Description

Background of the invention [0001] As many as nine million Americans over the age of 50 suffer from a condition called keratoconjunctivitis sicca, or dry eye syndrome. Discomfort from dry eye can range from mild burning to a constant chafing sensation under the eyelids. Dry eye is not only painful, but the condition can make you prone to eye infections and also produces blurred vision. It is believed that dry eye is caused by an inability to produce enough tears or inflammation of the outer eye. [0002] Previous and current efforts to treat dry eye include various artificial tear eye drops as well as eye drops containing cyclosporine, a drug used to reduce eye inflammation. Artificial tear eye drops and cyclosporine eye drops often cause local irritation, burning, and stinging, can blur vision, and are ineffective. In clinical trials of patients treated with cyclosporine eye drops, only 15% of patients treated with cyclosporine eye drops showed any increase in tear product...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/16
CPCA61K31/16A61K31/165A61K9/0043A61K31/167A61K31/565A61K9/06A61P27/02A61P29/00A61K31/573
Inventor J·伯恩斯坦
Owner WINSTON LAB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap